Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MLYCD | O95822 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420743 | 0.90 | HTT (0.40) | POLBKMT2AALDH1A1MAPTMLYCD | |
| SCHEMBL17583206 | 0.89 | POLB (0.37) | POLBMAPTMLYCDHTTSMN1; SMN2 | |
| SCHEMBL14477247 | 0.88 | POLB (0.35) | POLBMAPTMLYCDGABRA1GABRB2 | |
| SCHEMBL3891001 | 0.81 | KDM4E (0.48) | POLBKMT2AALDH1A1MAPTHTT | |
| SCHEMBL17420547 | 0.81 | ACACB (0.39) | POLBKMT2AALDH1A1MAPTHTT | |
| SCHEMBL161047 | 0.80 | MAPT (0.42) | POLBKMT2AALDH1A1MAPTHTT | |
| SCHEMBL17113764 | 0.80 | POLB (0.49) | POLBALDH1A1MAPTHTTSMN1; SMN2 | |
| SCHEMBL20406093 | 0.80 | KMT2A (0.41) | POLBKMT2AALDH1A1MAPTHTT | |
| SCHEMBL14466833 | 0.79 | KCNQ3 (0.42) | POLBHTTSMN1; SMN2GAAMAPK1 | |
| SCHEMBL17315771 | 0.79 | GAA (0.54) | POLBKMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556143-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9221791-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150099750-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-04-09 | — | — | US | disclosed |
| US-8901121-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140350003-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2014-11-27 | — | — | US | disclosed |
| US-8809378-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130005719-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | POLB 1777/4885KMT2A 1886/4885ALDH1A1 289/4885 |
| US-20150099750-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | POLB 1777/4885KMT2A 1886/4885ALDH1A1 289/4885 |
| US-20140350003-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | POLB 1777/4885KMT2A 1886/4885ALDH1A1 289/4885 |
| US-20130005719-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | POLB 1777/4885KMT2A 1886/4885ALDH1A1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.